AiViva is heading to BIO International 2025

We’re excited to announce that AiViva BioPharma will participate in the BIO International Convention 2025, which will take place this June in Boston!

With three clinical-stage programs and our proprietary JEL® long-acting injectable platform, AiViva is redefining how therapies are delivered. It focuses drugs precisely where needed, minimizing systemic exposure, and extending duration for up to six months. Our pipeline targets multi-billion-dollar markets across oncology, ophthalmology, and dermatology, with accelerated 505(b)(2) regulatory paths and IP protection into the 2040s.

We’re actively scheduling partnering meetings with investors, pharma partners, and innovators looking to collaborate.

Let’s meet in Boston and shape the next wave of targeted, long-acting therapies.  

Agustin de la Calle, Vice President of Business Development: 

• https://www.linkedin.com/in/agustin-de-la-calle-4b0136/
• office@aiviva.com